Search the GHTC website

Global health R&D delivers for New Mexico

US government investment in global health R&D has delivered

$92.7 million
to New Mexico research institutions
1,000+ new jobs
for New Mexico
New Mexico's top USG-funded global health R&D institutions

New Mexico's top USG-funded global health R&D institutions

University of New Mexico
$48.4 million
Los Alamos Scientific Laboratory
$9.8 million
New Mexico State University in Las Cruces
$9.6 million
Lovelace Biomedical
$8.9 million
VisionQuest Biomedical LLC
$7.9 million
Triad National Security LLC (Triad)
$2.5 million
Mesa Photonics LLC
$1.8 million
Spinceutica Inc.*
$1.4 million
Sandia Corp - Sandia National Laboratories
$686 thousand
The National Center for Genome Resources
$612 thousand
Westwind Computer Products
$474 thousand
Santa Fe Institute
$445 thousand
Creative LIBS Solutions
$183 thousand

New Mexico's top areas of global health R&D by USG funding

Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Reproductive health
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Diarrheal diseases
Emergent non-polio enteroviruses (including EV71, D68)
Filoviral diseases (including Ebola, Marburg)
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Global health R&D at work in New Mexico

University of New Mexico researchers have developed a rapid breath test to detect tuberculosis and other lung diseases, such as pneumonia and cystic fibrosis. The noninvasive, easy-to-use test offers results in ten minutes at the point of care without the need for expensive laboratory equipment. The test would represent a major step forward in terms of speed and portability by enabling doctors in low-resource settings to quickly detect lung infections and get patients on treatment. The technology has been licensed to a biotech company, which is continuing the development and commercialization of the tool.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PATH/Ruhani Kaur